MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 244 filers reported holding MYRIAD GENETICS INC in Q2 2017. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $4,752,000 | +157.4% | 248,504 | +124.4% | 0.00% | 0.0% |
| Q4 2016 | $1,846,000 | -21.5% | 110,742 | -3.1% | 0.00% | 0.0% |
| Q3 2016 | $2,352,000 | +211.9% | 114,272 | +363.7% | 0.00% | +100.0% |
| Q2 2016 | $754,000 | -40.0% | 24,646 | -26.9% | 0.00% | -33.3% |
| Q1 2016 | $1,256,000 | +162.2% | 33,708 | +139.8% | 0.00% | +200.0% |
| Q4 2014 | $479,000 | -100.0% | 14,056 | -99.3% | 0.00% | -99.1% |
| Q3 2014 | $82,313,627,000 | +15.0% | 2,134,136 | +16.0% | 0.11% | +23.6% |
| Q2 2014 | $71,590,654,000 | +25.5% | 1,839,431 | +10.2% | 0.09% | +39.1% |
| Q1 2014 | $57,060,751,000 | +42.8% | 1,668,931 | -12.3% | 0.06% | +28.0% |
| Q4 2013 | $39,946,969,000 | +361.0% | 1,904,050 | +416.4% | 0.05% | +138.1% |
| Q3 2013 | $8,665,625,000 | +59.3% | 368,750 | +82.2% | 0.02% | +50.0% |
| Q2 2013 | $5,438,488,000 | – | 202,400 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
| Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
| Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
| PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
| EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
| Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
| AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
| Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
| Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |